Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

BDRX Biodexa Pharmaceuticals PLC

0,9256

-0,1344 (-12,68%)

25 Jun 2024 - Geschlossen

Verzögert um 15 Minuten

Biotech Shares Bid Up Premarket Following 9.9% Institutional Stake Disclosure

With biotech stocks finding trememdous success in recent months, it’s no wonder why everyone wants to get in on the action, including institutional investors. After...

To read the full story on AllPennyStocks.com, click here.

Biodexa Pharmaceuticals (NASDAQ:BDRX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Biodexa Pharmaceuticals Charts.

Biodexa Pharmaceuticals (NASDAQ:BDRX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Biodexa Pharmaceuticals Charts.

News Biodexa Pharmaceuticals PLC

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)
Montag 24 Juni 2024 (18 Stunden vor) • GlobeNewswire Inc.

Results of Annual General Meeting
Donnerstag 13 Juni 2024 (2 Wochen vor) • GlobeNewswire Inc.

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona
Montag 10 Juni 2024 (2 Wochen vor) • GlobeNewswire Inc.

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
Mittwoch 22 Mai 2024 (1 Monat vor) • GlobeNewswire Inc.

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
Dienstag 21 Mai 2024 (1 Monat vor) • GlobeNewswire Inc.

Posting of Annual Report & Notice of AGM - Total Voting Rights
Mittwoch 15 Mai 2024 (1 Monat vor) • GlobeNewswire Inc.

Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
Dienstag 30 April 2024 (2 Monate vor) • GlobeNewswire Inc.

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
Freitag 26 April 2024 (2 Monate vor) • GlobeNewswire Inc.

Preliminary Results for the Year Ended 31 December 2023
Freitag 19 April 2024 (2 Monate vor) • GlobeNewswire Inc.

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
Freitag 23 Februar 2024 (4 Monate vor) • GlobeNewswire Inc.

Biotech Shares Bid Up Premarket Following 9.9% Institutional Stake Disclosure
Dienstag 13 Februar 2024 (4 Monate vor) • AllPennyStocks.com

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
Donnerstag 8 Februar 2024 (5 Monate vor) • GlobeNewswire Inc.

Weitere Biodexa Pharmaceuticals PLC News-Artikel

Atlas 2023-1 61

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen